EMA revises guidance for medicines development in Alzheimer’s disease European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a revised guideline on clinical studies for medicines that target Alzheimer’s disease.…
Working to reverse the cognitive decline of dementia The end of Alzheimer’s: the first programme to prevent and reverse the cognitive decline of dementia, by Dale E Bredesen…
Promising Alzheimer’s drug disappoints in phase III trials Drug that appeared a promising candidate for treating Alzheimer’s has failed to show benefits in phase III trials…
Turning off the Huntington’s gene Initial safety and tolerability trials of breakthrough Huntington’s therapy are a success, but we must await judgment on clinical efficacy.…
Slowing disease progress primary concern for MS patients, survey finds Efficacy is the greatest concern for patients with multiple sclerosis when considering treatment options, according to an international survey of more than 1000 people…
Antihistamine shows potential to repair neuron damage in multiple sclerosis Research shows an over-the-counter antihistamine could act as a remyelinating agent in multiple sclerosis…
Antidepressant nortriptyline could slow Parkinson’s pathology The drug could be used as a multi-functional compound to treat comorbid depression in Parkinson’s disease and also slow down the progress of the disease, researchers say.…
MHRA advises health professionals on supply of clobazam for epilepsy An epilepsy charity has updated its advice for health professionals on the supply of clobazam for people with epilepsy.…
MS charity says cannabis should be legalised for medicinal use Cannabis should be legalised for medicinal use for people with multiple sclerosis (MS) to relieve their pain, a leading charity has advised.…
Analysis estimates more than 30 Alzheimer’s drugs will have launched by 2022 Over the next 5 years, 27 phase III and 8 phase II Alzheimer’s drugs may be launched, according to a pipeline analysis carried out by ResearchersAgainstAlzheimer’s…
